ClinicalTrials.gg
RecruitingNCT07099976PIONEERSUpdated Apr 29, 2026

PromotIng Optimal Treatment for Community-acquired PNeumonia in EmErgency Rooms

An interventional study of The novel care pathway intervention and Usual Care Alone in Community-Acquired Pneumonia (CAP) and Pneumonia, sponsored by Jeffrey Pernica. Recruiting at 6 sites in Canada. Open to participants aged 6 Months to 18 Years. Per ClinicalTrials.gov, last updated 2026-04-29.

Sponsored by Jeffrey Pernica · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
698
Allocation
Randomized
Ages
6 Months to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Community-Acquired Pneumonia with a site in Canada — 7 open to participants now, 7 under way, 4 of them phase 3. Community-Acquired Pneumonia · Canada.

Planned enrollment
4th of 11
698 · median 219
Started
2026
with 1 other
No phase
3 of 15
2 open now
Registered
15th of 15
by date
Lead sponsor
2 of 15
Jeffrey Pernica

Among the 15 studies in Community-Acquired Pneumonia with a site in Canada, this one is the 4th largest by planned enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2026, is one of 3 with no phase, and was the 15th registered.

Community-Acquired Pneumonia

325 studies on the registry are indexed under Community-Acquired Pneumonia; 77 are open to participants now.

Browse Community-Acquired Pneumonia studies →

Open to participants now

7 of the 15 studies in Community-Acquired Pneumonia with a site in Canada are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 41 Community-Acquired Pneumonia studies recruiting now, 29 (71%) set no upper age limit and 9 (22%) stop at 75 or younger; 13 take children under 18; 5 take healthy volunteers.

This study: 6 Months to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Community-Acquired Pneumonia with a site in Canada, or all of them as a file.
02

Study summary

In North America, up to 5% of preschoolers develop community-acquired pneumonia (CAP) every year. Pneumonia is the second-leading reason for paediatric hospitalization in both Canada and the US; approximately 20% of children hospitalized with CAP may need intensive care, which can result in significant morbidity. Given this burden of disease, it is critical that CAP is managed appropriately. Specific therapy for CAP is dependent on microbiologic aetiology, as bacterial disease will improve with antibiotic treatment.

Read the detailed description

Unfortunately, there are no features on history or physical examination that are highly specific for either viral or bacterial disease. Although bacterial disease is more often associated with consolidations, validated radiographic criteria for reliably distinguishing between viral and bacterial pneumonia do not exist. Furthermore, children, unlike adults, commonly develop viral pneumonia or bacterial-viral coinfections; one large prospective study of children hospitalized with CAP in the USA reported that 66% had a respiratory virus detected and 26% had proven coinfections. Consequently, though physicians are aware that antibiotics do not improve the course of children with viral illnesses, the inability to reliably discriminate between viral and bacterial disease results in the vast majority of children with even non-severe CAP (ie. that can be managed as an outpatient) receiving antibiotics. This may be because clinicians are not aware how much paediatric CAP is viral, but is probably also related to physician beliefs/attitudes. These include the desire to be 'safe', the belief that families want antibiotics, and the perception that it is easier and quicker to prescribe than to explain why antibiotics are not required.

Minimizing inappropriate antimicrobial prescribing is an important strategy to prevent further emergence of circulating antimicrobial resistance. The WHO's Global Action Plan on Antimicrobial Resistance states that 'evidence-based prescribing should be the standard of care'. Optimizing antimicrobial prescribing, also known as 'antimicrobial stewardship', is the main strategy to deal with escalating antimicrobial resistance and has been called 'a fiduciary responsibility for all healthcare institutions across the continuum of care'. Antibiotic stewardship is critical to reducing the dramatic increase in antimicrobial resistance seen in Canada and worldwide, which is why CIHR continues to encourage antimicrobial stewardship research. The Public Health Agency of Canada's 2023 Pan-Canadian Action Plan on Antimicrobial Resistance explicitly calls for research to 'support the development and uptake of diagnostics…that support antimicrobial stewardship, including point-of-care tools'. Antimicrobials routinely prescribed to children can produce problematic side effects and impact normal microbiota, which can influence the development of obesity, atopy, and other disorders.

It has now been definitively established that short course (3-5 day) antibiotic treatment is equally effective as longer courses of antibiotics for non-severe paediatric CAP. The investigators conducted the first of these trials to be published, a multi-year RCT at McMaster Children's Hospital (MCH) and the Children's Hospital of Eastern Ontario (CHEO), enrolling children with non-severe CAP, randomizing to either 5 or 10 days of amoxicillin (duration blinded using placebos), and demonstrated that clinical response at 14-21 days was comparable between groups. Shortening durations further would not seem advisable, given that one trial in Israel found more failures in children given 3 days of antibiotics and that it has been shown that 3 days of antibiotics is superior to placebo for the treatment of paediatric CAP. The investigators believe a better strategy would be to determine how to better identify children with purely viral disease, given that these cases represent the majority of paediatric CAP, and/or enable front-line clinicians to more effectively withhold antibiotics entirely from children at lower risk of bacterial disease. (The investigators note that in these referenced randomized trials and systematic reviews, antibiotic treatment was not associated with large improvements in cure rates; this probably speaks to the fact that only a small proportion of paediatric CAP is bacterial, as reliable discrimination between viral and bacterial disease is not possible on clinical grounds.)

There have been efforts to use biomarkers alone to improve prescribing for respiratory infections. One systematic review found that point-of-care C-reactive protein (POC CRP) testing was associated with significantly decreased antibiotic prescribing for those with acute respiratory infections (not confirmed bacterial disease) presenting to primary care (RR 0.77, 95%CI 0.69-0.86, 12 trials [10218 participants], moderate-certainty evidence). Although the performance characteristics of this test are insufficiently good to recommend its use in isolation, this evidence would suggest that this assay could play a useful role when integrated into a care pathway. Other biomarkers have not been proven to improve prescribing; one Swiss study using procalcitonin to guide antibiotic treatment for paediatric CAP did not find any benefit. However, this may well have been due to the fact that standard prescribing practices at these Swiss centres were already extremely good, as only 56% of children in the control group were given antibiotics. North American clinicians are much more liberal with antibiotic prescribing for CAP; unpublished MCH and CHEO data indicate that 99% of children diagnosed with CAP in the paediatric ED receive antibiotics, and American data show that most children diagnosed with CAP at outpatient clinics and EDs are also treated.

There have been very few trials investigating care pathways to improve antibiotic treatment of children with non-severe CAP in the ED. One cluster-randomized trial enrolled children with respiratory infections to assess the utility of an online digital calculator (developed to predict the likelihood of bacterial infections using many clinical and laboratory variables), where those randomized to the intervention arm were only prescribed antibiotics if the probability of bacterial disease was >10%; unfortunately, only 315/995 participants had CAP and there was no effect observed of the intervention on antibiotic use. Another study done in Italy using a different paediatric CAP care pathway did not even attempt to decrease unnecessary prescribing.

Overall, the effectiveness of care pathways will vary widely depending on how they are constructed and by what constitutes local standard of care. In the PIONEER pilot study that just finished enrolling at MCH, 100% of participants with CAP who received standard care received antibiotics, whereas only 53% of participants with CAP whose care was guided by the novel care pathway (the intervention of interest) were prescribed antibiotics within 14 days. The absolute benefit of our intervention may prove to be substantially larger than that reported for other stewardship interventions aiming to improve antimicrobial use for respiratory infections.

03

Conditions studied

  • Community-Acquired Pneumonia (CAP)
  • Pneumonia

Keywords

  • Pneumonia
  • Antibiotics
04

Who can participate

Ages eligible
6 Months to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Children aged 6 month to 18 years presenting to the Emergency Department who are diagnosed with CAP and are well enough to be discharged home (i.e. 'non-severe' CAP) will be eligible. They must have a fever (on exam or by history) and at least one of:

  • Tachypnoea measured at triage (>60 bpm for age \<1, >50 for 1-2 years of age, >40bpm for 2-4 years of age, and >30bpm for >4 years of age)
  • Cough on exam or by history
  • Increased work of breathing on exam
  • Auscultatory finding (focal crackles, bronchial breathing, etc.) consistent with CAP

Exclusion criteria

Exclusion Criteria:

Children will be excluded if they have any of the following

  • Cystic Fibrosis
  • Anatomic Lung Disease
  • Bronchiectasis
  • Chronic Lung Disease requiring home oxygen or home ventilation
  • Congenital heart Disease (requiring specific medical treatment or with exercise restrictions),
  • History of repeated aspiration/velopharyngeal incompetence
  • Immunodeficiency (primary, acquired or iatrogenic)
  • Pneumonia previously (clinically) diagnosed within the past month (that was presumed to have resolved prior to the episode prompting the current visit to the ED)
  • Lung abscess within the past 6 months
  • Children who present with ongoing fever after 4 days of amoxicillin, cefprozil, cefuroxime, levofloxacin, moxifloxacin or doxycycline are not eligible; as this duration of therapy with these drugs would normally be sufficient to treat bacterial CAP, a different approach would be required (ie. the care pathway as written might not be appropriate).
  • Children will not be eligible to participate more than once
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
698 participants (estimated)

Study arms

  • Experimental
    The novel care pathway intervention

    The novel care pathway intervention will incorporate multiple factors to determine risk of bacterial CAP. At recruitment, POC CRP testing, and bioMérieux Spotfire testing of nasopharyngeal swabs (NPS) will identify those who are at appreciable risk and will receive a prescription for antibiotic treatment on day 0. Please refer to the Specimen Collection and Processing manual for more specific information on the collection process. Appreciable-risk participants will be referred back to the clinical team to be given amoxicillin, the current standard of care in Canada (those with penicillin allergy will presumably receive an appropriate substitution as per local guidelines). Low-risk participants will be discharged home without antibiotics.

    Diagnostic Test: The novel care pathway intervention

  • Active comparator
    Control Group

    Participants will be recruited in the ED and will be managed as per the treating clinician; the study team will not influence management

    Other: Usual Care Alone

Interventions

  • Diagnostic testThe novel care pathway intervention

    The pathway uses already-ascertained data, bioMérieux Spotfire testing, and POC CRP testing to stratify patients into risk categories. The first step in the pathway will be POC CRP testing; children with CRP \> 60 mg/L will be deemed 'appreciable risk', whereas those with CRP \< 20 mg/L will be deemed 'low risk'. The CRP cut-offs of 20mg/L (more sensitive) and 60mg/L (more specific) were selected after reviewing the literature, with particular emphasis on meta-analyses; other large recent studies have also used 60mg/L as an upper cut-off for bacterial infection. Participants with CRP between 20-60mg/L will be categorized further to identify children either more likely to have bacterial pneumonia or more intolerant of misclassification. 'If they have O2 saturation \<95% AND tachypnoea as per age-specific norms, they will be 'appreciable risk' (\>60 bpm for age \<1 y, \>50 bpm for 1-2 y, \>40 bpm for 2-4 y, and \>30 bpm for \>4 y).

  • OtherUsual Care Alone

    Participants will be recruited in the ED and will be managed as per the treating clinician; the study team will not influence management.

06

What researchers measure

Primary outcomes

  1. Antibiotic use for CAP or respiratory tract infection before day 7 post-enrolment

    The proportion of patients who receive antibiotics.

    Time frame: From enrollment to 7 days post enrollment

  2. Early clinical response (ECR, clinical improvement in symptoms and lack of requirement for additional antibacterials as measured at day 4).

    At baseline/enrollment, caregivers will be asked to rank all of the child's symptoms (work of breathing, dyspnoea \[for children over the age of 7\], oral intake, and activity level) as compared to normal. These will be categorized as the following: "same as normal", "a little worse than normal", and "a lot worse than normal". At the day 4, and day 15 follow-ups, caregivers will be asked to rank the child's symptoms as compared to the previous visit. These will be categorized as the following: "worse", "about the same", "a little better", "a lot better". Clinical response requires at least "a little better" for any symptom that was not "same as normal" at baseline. Dyspnoea will be self-reported in children over the age of seven. For those under seven, dyspnoea will not be reported.

    Time frame: From enrollment to day 4

Secondary outcomes

  1. Ordinal outcome variable

    This variable will include early clinical response, drug adverse events, and hospitalization to generate an ordinal outcome variable with ranks 1-8. Ranks 1-3 have ECR being met with no AEs; mild-moderate AEs; and severe AEs, respectively. Ranks 4-6 are associated with NOT achieving ECR with no AEs; mild-moderate AEs; and severe AEs, respectively. Rank 7 is no ECR plus hospitalization with no AEs, and rank 8 is no ECR with hospitalization and any AE.

    Time frame: From enrollment to end of 30 day follow up

  2. Time to resolution of both fever and iincreases work of breathing

    Time frame: From enrollment to end of 30 day follow up

  3. Late clinical response

    Defined same as early clinical response but measured at day 15 as compared to day 4

    Time frame: From enrollment to day 15

  4. Proportion of participants with antibiotic use specifically for CAP or respiratory tract infection before day 30

    Time frame: From enrollment to end of 30 day follow up

  5. Hospitalization for CAP before day 30

    Time frame: From enrollment to end of 30 day follow up

  6. The occurrence of drug-related adverse events

    Time frame: From enrollment to end of 30 day follow up

  7. The occurrence of severe drug-related adverse events

    Time frame: From enrollment to end of 30 day follow up

  8. Unscheduled ED or urgent care visits before day 15

    Time frame: From enrollment to day 15

  9. The development of complicated CAP (i.e. pleural effusion/empyaema) before day 15

    Time frame: From enrollment to day 15

  10. The number of days that participants miss school/daycare before day 15

    Time frame: From enrollment to day 15

  11. The acceptability of the care plan from the caregiver's perspective on day 0 and day 30

    Questionnaire given to parents to assess the acceptability of the care plan will be completed on day 30. This is a 6-point Likert scale ranging from 'extremely satisfied' to 'not at all satisfied'

    Time frame: From enrollment to end of 30 day follow up

  12. The number of days that participant's caregivers have work disrupted before day 15

    Time frame: From enrollment to day 15

07

Study locations

2 of 6 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Apr 2030, 48 months after the start.

Of 42 non-industry interventional studies with no phase under Community-Acquired Pneumonia, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 38. This study's planned 48 months is above that.

Counting every sponsor, half of 43 studies reached it within 24 months; a quarter within 14 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2025
First posted
Aug 1, 2025
StartActual
Apr 15, 2026
Primary completionEst.
Apr 15, 2030
CompletionEst.
May 15, 2030
Last update
Apr 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07099976
Lead sponsor
Jeffrey Pernica
Responsible party
Jeffrey Pernica (Associate Professor, McMaster University) — Sponsor-investigator
First posted
Aug 1, 2025
Start date
Apr 15, 2026
Primary completion
Apr 15, 2030 (estimated)
Completion
May 15, 2030 (estimated)
Last update
Apr 29, 2026

Study contacts

Jeffrey Pernica, MD
Contact
pernica@mcmaster.ca
905-521-2100 ext. 77577

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion